A Reversal on Sequencing? Proposed Legislation Would Allow Patenting of Naturally Occurring Genes
FDA Law
OCTOBER 24, 2024
Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. They argued that the legislation was necessary to spur innovation of new vaccines and therapies in response to emerging health threats.
64 
Let's personalize your content